Wyeth Pharmaceuticals, a division of Wyeth, announced that Pristiq (desvenlafaxine), a new serotonin-norepinephrine reuptake inhibitor (SNRI) approved to treat adult patients with major depressive disorder (MDD), is now available in US retail pharmacies nationwide. The recommended dose of Pristiq is 50 milligrams (mg) once daily. The company begins full-scale selling and educational efforts regarding Pristiq for physicians this week.
The details can be read here.
No comments:
Post a Comment